Angiogenesis in rheumatoid arthritis: A disease specific process or a common response to chronic inflammation?

Autoimmunity Reviews

Volumn 10, Issue 10, 2011, Pages 595-598

  Marrelli, Alessandra ^a   Cipriani, Paola ^a   Liakouli, Vasiliki ^a   Carubbi, Francesco ^a   Perricone, Carlo ^b   Perricone, Roberto ^c   Giacomelli, Roberto ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Angiogenesis; Anti TNF; Inflammation; Rheumatoid arthritis; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; CHRONIC INFLAMMATION; FIBROBLAST; HUMAN; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; STROMA CELL; SYNOVIUM;

ANGIOPOIETINS; ANIMALS; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; HUMANS; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80051669017     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.020     Document Type: Review

References (43)

1. Vergunst C.E., van der Sande M.G., Lebre M.C., Tak P.P. The role of chemokines in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 2005, 34:415-425.
2. Smith M.D., Barg E., Weedon H., Papangelis V., Smeets T., Tak P.P., et al. Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. Ann Rheum Dis 2003, 62:303-307.
3. Paleolog E.M. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002, 4(Suppl 3):S81-S90.
4. Paleolog E.M., Fava R.A. Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies. Semin Immunopathol 1998, 20:73-94.
5. Stevens C.R., Blake D.R., Merry P., Revell P.A., Levick J.R. A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum 1991, 34:1508-1513.
6. Stevens C.R., Williams R.B., Farrell A.J., Blake D.R. Hypoxia and inflammatory synovitis: observations and speculation. Ann Rheum Dis 1991, 50:124-132.
7. FitzGerald O., Soden M., Yanni G., Robinson R., Bresnihan B. Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis. Ann Rheum Dis 1991, 50:792-796.
8. Ceponis A., Konttinen Y.T., Imai S., Tamulaitiene M., Li T.F., Xu J.W., et al. Synovial lining, endothelial and inflammatory mononuclear cell proliferation in synovial membranes in psoriatic and reactive arthritis: a comparative quantitative morphometric study. Br J Rheumatol 1998, 37:170-178.
9. Taylor P.C., Sivakumar B. Curr Opin Rheumatol 2005, 17:293-298.
10. O'Hara R., Murphy E.P., Whitehead A.S., FitzGerald O., Bresnihan B. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res 2000, 2:142-144.
11. Connolly M., Marrelli A., Blades M., McCoemick J., Maderna P., Godson C., et al. Acute serum amyloid a induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid/scid mouse chimera model. J Immunol 2010, 184:6427-6437.
12. Monaco C., Andreakos E., Kiriakidis S., Feldmann M., Paleolog E. T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy 2004, 3:335-342.
13. Kasama T., Miwa Y., Isozaki T., Odai T., Adachi M., Kunkel S.L. Neutrophil-derived cytokines: potential therapeutic targets in inflammation. Curr Drug Targets Inflamm Allergy 2005, 4:273-279.
14. Koch A.E. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis 2000, 59:65-71.
15. Walsh D.A., Pearson C.I. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 2001, 3:147-153.
16. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
17. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
18. Semenza G.L. HIF-1, O2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001, 107:1-3.
19. Gaber T., Dziurla R., Tripmacher R., Burmester G.R., Buttgereit F. Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do!. Ann Rheum Dis 2005, 64:971-980.
20. Peters C.L., Morris C.J., Mapp P.I., Blake D.R., Lewis C.E., Winrow V.R. The transcription factors hypoxia-inducible factor 1alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum 2004, 50:291-296.
21. Hitchon C., Wong K., Ma G., Reed J., Lyttle D., El-Gabalawy H. Hypoxia-induced production of stromal cellderived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 2002, 46:2587-2597.
22. Hollander A.P., Corke K.P., Freemont A.J., Lewis C.E. Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 2001, 44:1540-1544.
23. Lee S.S., Joo Y.S., Kim W.U., Min D.J., Park S.H., Cho C.S. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001, 19:321-324.
24. Paleolog E.M., Young S., Stark A.C., McCloskey R.V., Feldmann M., Maini R.N. Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNF and IL-1 in rheumatoid arthritis. Arthritis Rheum 1998, 41:1258-1265.
25. Ballara S.C., Taylor P.C., Reusch P., Marme' D., Feldmann M., Maini R.N., et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001, 44:2055-2064.
26. Macias I., Garcia-Perez S., Ruiz-Tudela M., Medina F., Chozas N., Giron-Gonzales J.A. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. J Rheumatol 2005, 32:2102-2108.
27. Fava R.A., Olsen N.J., Spencer-Green G., Yeo T.K., Berse B., Jackman R.W., et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994, 180:341-346.
28. Pufe T., Petersen W., Tillmann B., Mentlein R. Splice variants VEGF121 and VEGF165 of the angiogenic peptide vascular endothelial cell growth factor are expressed in the synovial tissue of patients with rheumatoid arthritis. J Rheumatol 2001, 28:1482-1485.
29. Kasama T., Kobayashi K., Yajima N., Shiozawa F., Yoda Y., Takeuchi H.T., et al. Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA). Clin Exp Immunol 2000, 121:533-535.
30. Ikeda M., Hosoda Y., Hirose S., Okada Y., Ikeda E. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 2000, 191:426-433.
31. Vadasz Z., Attias D., Kessel A., Toubi E. Neuropilins and semaphorins-from angiogenesis to autoimmunity. Autoimmun Rev 2010, 9:825-829.
32. Fiedler U. Augustin HG angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006, 12:552-558.
33. DeBusk L.M., Chen Y., Nishishita T., Chen J., Thomas J.W., Lin P.C. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2003, 9:2461-2471.
34. Fiedler U., Reiss Y., Scharpfenecker M., Grunow V., Koidi S., Thurston G., et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006, 2:235-239.
35. Beck L., D'Amore P.A. Vascular development: cellular and molecular regulation. FASEB J 1997, 5:365-373.
36. Darland D.C., D'Amore P.A. Blood vessel maturation: vascular development comes of age. Clin Invest 1999, 2:57-58.
37. Izquierdo E., Cañete J.D., Celis R., Santiago B., Usategui A., Sanmartí R., et al. Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS One 2009, 12:8131.
38. Ellis L.M. Hicklin DJ VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
39. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159-165.
40. Del Rey M.J., Izquierdo E., Usategui A., Gonzalo E., Blanco F.J., Acquadro F., et al. The transcriptional response of normal and rheumatoid arthritis synovial fibroblasts to hypoxia. Arthritis Rheum 2010, 12:3584-3594.
41. Del Rey M.J., Izquierdo E., Caja S., Usategui A., Santiago B., Galindo M., et al. Human inflammatory synovial fibroblasts induce enhanced myeloid cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 1alpha/vascular endothelial growth factor-mediated pathway in immunodeficient mice. Arthritis Rheum 2009, 10:2926-2934.
42. Kaplan M.J. Endothelial damage and autoimmune diseases. Autoimmunity 2009, 42:561-562.
43. Bagli E., Xagorari A., Papetropoulos A., Murphy C., Fotsis T. Angiogenesis in inflammation. Autoimmun Rev 2004, 3(Suppl 1):S26.